Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKinsey
AstraZeneca
Colorcon
Baxter

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for N91115

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for N91115?

N91115 is an investigational drug.

There have been 8 clinical trials for N91115. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2019.

The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and Asthma. The leading clinical trial sponsors are Nivalis Therapeutics, Inc., University of North Carolina, Chapel Hill, and National Heart, Lung, and Blood Institute (NHLBI).

There are ten US patents protecting this investigational drug and forty-five international patents.

Recent Clinical Trials for N91115
TitleSponsorPhase
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyNational Heart, Lung, and Blood Institute (NHLBI)Phase 2
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyUniversity of North Carolina, Chapel HillPhase 2
MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)Nivalis Therapeutics, Inc.Phase 1

See all N91115 clinical trials

Clinical Trial Summary for N91115

Top disease conditions for N91115
Top clinical trial sponsors for N91115

See all N91115 clinical trials

US Patents for N91115

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
N91115   Start Trial Solid forms of an S-Nitrosoglutathione reductase inhibitor LAUREL THERAPEUTICS LTD. (Hangzhou, Zhejiang Province, CN)   Start Trial
N91115   Start Trial Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors N30 Pharmaceuticals, Inc. (Boulder, CO)   Start Trial
N91115   Start Trial Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors N30 Pharmaceuticals, Inc. (Boulder, CO)   Start Trial
N91115   Start Trial Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors Nivalis Therapeutics, Inc. (Boulder, CO)   Start Trial
N91115   Start Trial Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors Nivalis Therapeutics, Inc. (Boulder, CO)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for N91115

Drugname Country Document Number Estimated Expiration Related US Patent
N91115 World Intellectual Property Organization (WIPO) 2017044766 2035-09-10   Start Trial
N91115 World Intellectual Property Organization (WIPO) 2017044788 2035-09-10   Start Trial
N91115 Australia 2011343518 2030-12-16   Start Trial
N91115 Brazil 112013014681 2030-12-16   Start Trial
N91115 Canada 2821412 2030-12-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Medtronic
Baxter
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.